The Effect Of AVANDIA On The Late Asthmatic Response
- Registration Number
- NCT00318630
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study is to investigate the effects of AVANDIA on the asthmatic response.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Subjects receiving treatment 1 Placebo Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet. Subjects receiving treatment 2 Placebo Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days. Subjects receiving treatment 1 Rosiglitazone Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet. Subjects receiving treatment 2 Rosiglitazone Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
- Primary Outcome Measures
Name Time Method The effect of repeat oral doses of AVANDIA for 28 days on the late asthmatic response to inhaled allergen. Measured as lung function 4-10 hours after allergen challenge after 28 days dosing. Up to 43 days
- Secondary Outcome Measures
Name Time Method The early asthmatic response to allergen, bronchial challenge, nitric oxide, markers of inflammation and safety/tolerability. Up to 43 days
Trial Locations
- Locations (1)
GSK Investigational Site
🇳🇿Wellington, New Zealand